Cargando…
A Critique of the Drug Discovery and Phase 3 Clinical Programs Targeting the Amyloid Hypothesis for Alzheimer Disease
Autores principales: | Karran, Eric, Hardy, John |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4204160/ https://www.ncbi.nlm.nih.gov/pubmed/24853080 http://dx.doi.org/10.1002/ana.24188 |
Ejemplares similares
-
The amyloid hypothesis of Alzheimer's disease at 25 years
por: Selkoe, Dennis J, et al.
Publicado: (2016) -
A critique of statistical hypothesis testing in clinical research
por: Raha, Somik
Publicado: (2011) -
Reconsideration of Amyloid Hypothesis and Tau Hypothesis in Alzheimer's Disease
por: Kametani, Fuyuki, et al.
Publicado: (2018) -
Can an Infection Hypothesis Explain the Beta Amyloid Hypothesis of Alzheimer’s Disease?
por: Fulop, Tamas, et al.
Publicado: (2018) -
Intracellular amyloid hypothesis for ultra‐early phase pathology of Alzheimer's disease
por: Okazawa, Hitoshi
Publicado: (2021)